Published on
Dec 18, 2024
Antibody drug has promise as “next frontier” in inflammatory bowel disease
With its best-in-class potential, the biologic could provide a new treatment option for patients with inflammatory bowel disease (IBD), say Teva Pharmaceuticals and Sanofi. The first randomised, placebo-controlled study to evaluate the impact of an anti- …
Source:
European Pharmaceutical Review
-
Neutral
